Superworth

Insulet price to sales ratio PODD

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026
3.4×
10-year median
10.2×
Against its 10-year history
2nd
percentile: 0 is its lowest day, 100 its highest
10-year range
3.0× to 22.1×
Peer median
3.5×

Insulet's price to sales ratio is 3.4× as of Oct 23, 2026.

That is below its ten-year median of 10.2×, lower than on 98% of days in the last ten years.

Over that time it ranged from 3.0× in Oct 2026 to 22.1× in Jan 2021.

The median for 10 medical instruments and supplies stocks of a similar size is 3.5×.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far3.4×3.0×8.1×
20258.1×8.1×10.4×
20249.4×6.5×9.5×
20239.7×6.3×17.1×
202216.4×12.1×17.6×
202117.7×16.1×22.1×
202019.4×12.1×20.2×
201915.4×8.2×16.5×
20188.7×8.2×12.6×
20179.2×6.0×9.4×
20166.0×4.5×7.1×
20157.3×5.5×8.9×
20149.1×7.1×11.1×
20138.6×5.1×9.3×
20125.0×4.9×6.2×

Against its peers

Companies in Medical - Instruments & Supplies nearest Insulet's size, closest first, today.

CompanyPrice to sales ratio
PODDInsulet3.4×
GMEDGlobus Medical3.5×
ALGNAlign Technology2.7×
COOCooper Companies2.7×
PENPenumbra8.5×
SOLVSolventum1.7×
MSAMSA Safety3.6×
MMSIMerit Medical Systems3.5×
HAEHaemonetics4.0×
VNTVontier1.5×
BMIBadger Meter5.0×
Peer median3.5×

Where Insulet ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Insulet

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.